Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MGNX's Cash to Debt is ranked higher than
86% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. MGNX: No Debt )
MGNX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.72
MGNX's Equity to Asset is ranked higher than
76% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MGNX: 0.72 )
MGNX' s 10-Year Equity to Asset Range
Min: -0.26   Max: 0.73
Current: 0.72

-0.26
0.73
Interest Coverage No Debt
MGNX's Interest Coverage is ranked higher than
61% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MGNX: No Debt )
MGNX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 8.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -39.32
MGNX's Operating margin (%) is ranked higher than
76% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. MGNX: -39.32 )
MGNX' s 10-Year Operating margin (%) Range
Min: 0.63   Max: 12.86
Current: -39.32

0.63
12.86
Net-margin (%) -39.32
MGNX's Net-margin (%) is ranked higher than
76% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. MGNX: -39.32 )
MGNX' s 10-Year Net-margin (%) Range
Min: -0.45   Max: 13.1
Current: -39.32

-0.45
13.1
ROE (%) -22.10
MGNX's ROE (%) is ranked higher than
77% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. MGNX: -22.10 )
MGNX' s 10-Year ROE (%) Range
Min: -0.74   Max: -0.74
Current: -22.1

ROA (%) -14.47
MGNX's ROA (%) is ranked higher than
78% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. MGNX: -14.47 )
MGNX' s 10-Year ROA (%) Range
Min: -0.29   Max: 14.36
Current: -14.47

-0.29
14.36
ROC (Joel Greenblatt) (%) -438.40
MGNX's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. MGNX: -438.40 )
MGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 8.82   Max: 502.14
Current: -438.4

8.82
502.14
» MGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MGNX Guru Trades in Q4 2013

John Griffin 900,000 sh (New)
» More
Q1 2014

MGNX Guru Trades in Q1 2014

Steven Cohen 870,189 sh (New)
John Griffin 900,000 sh (unchged)
» More
Q2 2014

MGNX Guru Trades in Q2 2014

Jean-Marie Eveillard 334,285 sh (New)
George Soros 19,488 sh (New)
John Griffin 900,000 sh (unchged)
Steven Cohen 2,017,066 sh (unchged)
» More
Q3 2014

MGNX Guru Trades in Q3 2014

Ronald Muhlenkamp 16,975 sh (New)
John Griffin 1,350,000 sh (+50%)
George Soros 19,488 sh (unchged)
Jean-Marie Eveillard 334,285 sh (unchged)
Steven Cohen 1,521,100 sh (-24.59%)
» More
» Details

Insider Trades

Latest Guru Trades with MGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Griffin 2014-09-30 Add 50%0.11%$18.37 - $22.63 $ 27.7634%1350000
Ronald Muhlenkamp 2014-09-30 New Buy0.06%$18.37 - $22.63 $ 27.7634%16975
Jean-Marie Eveillard 2014-06-30 New Buy0.02%$18.26 - $29.47 $ 27.7632%334285
George Soros 2014-06-30 New Buy$18.26 - $29.47 $ 27.7632%19488
John Griffin 2013-12-31 New Buy0.25%$21.82 - $28.48 $ 27.766%900000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Macrogenics Inc

Weekly 3-Year Low Highlights: KN, MGNX, MIXT, EDMC
According to GuruFocus list of three-year lows, Knowles Corporation, Macrogenics Inc., MiX Telematics Ltd. and Education Management Corp have all reached their three-year lows. Read more...

Ratios

vs
industry
vs
history
P/B 5.57
MGNX's P/B is ranked higher than
74% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. MGNX: 5.57 )
MGNX' s 10-Year P/B Range
Min: 3.33   Max: 12.85
Current: 5.57

3.33
12.85
P/S 12.69
MGNX's P/S is ranked higher than
86% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. MGNX: 12.69 )
MGNX' s 10-Year P/S Range
Min: 1.12   Max: 7.51
Current: 12.69

1.12
7.51
EV-to-EBIT -26.51
MGNX's EV-to-EBIT is ranked higher than
75% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MGNX: -26.51 )
MGNX' s 10-Year EV-to-EBIT Range
Min: -38   Max: 1227.8
Current: -26.51

-38
1227.8
Current Ratio 7.19
MGNX's Current Ratio is ranked higher than
82% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. MGNX: 7.19 )
MGNX' s 10-Year Current Ratio Range
Min: 1.35   Max: 7.19
Current: 7.19

1.35
7.19
Quick Ratio 7.19
MGNX's Quick Ratio is ranked higher than
83% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. MGNX: 7.19 )
MGNX' s 10-Year Quick Ratio Range
Min: 1.35   Max: 7.19
Current: 7.19

1.35
7.19

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.22
MGNX's Price/Net Cash is ranked higher than
87% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. MGNX: 6.22 )
MGNX' s 10-Year Price/Net Cash Range
Min: 4.46   Max: 9.94
Current: 6.22

4.46
9.94
Price/Net Current Asset Value 6.01
MGNX's Price/Net Current Asset Value is ranked higher than
86% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. MGNX: 6.01 )
MGNX' s 10-Year Price/Net Current Asset Value Range
Min: 4.31   Max: 9.73
Current: 6.01

4.31
9.73
Price/Tangible Book 5.57
MGNX's Price/Tangible Book is ranked higher than
80% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. MGNX: 5.57 )
MGNX' s 10-Year Price/Tangible Book Range
Min: 3.99   Max: 8.76
Current: 5.57

3.99
8.76
Price/Median PS Value 2.06
MGNX's Price/Median PS Value is ranked higher than
74% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. MGNX: 2.06 )
MGNX' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 1.53
Current: 2.06

0.34
1.53
Earnings Yield (Greenblatt) -3.80
MGNX's Earnings Yield (Greenblatt) is ranked higher than
74% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. MGNX: -3.80 )
MGNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 0.7
Current: -3.8

0.1
0.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:M55.Germany
Macrogenics Inc was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company, engaged in discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The Company currently has a manufacturing facility located in Rockville, Maryland. The Company has three versatile, proprietary technology platforms consisting of: its Dual Affinity Re-Targeting ("DART") platform, which enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, and also includes the ability to recruit any T cell in a patient's body to destroy targeted cancer cells; its Fc Optimization platform, which enhances the body's immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular cytotoxicity ("ADCC") in which antibodies and immune cells cooperate to destroy targets such as tumor cells; and its Cancer Stem-like Cell ("CSLC") platform, which provides a discovery tool to identify cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them. It currently has two oncology product candidates in clinical development. The product candidates are subject to regulation in the United States by the Food and Drug Administration as biological products.
» More Articles for MGNX

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: KN, MGNX, MIXT, EDMC May 27 2014 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Nov 25 2014
Macrogenics (MGNX) Is Strong On High Volume Today Nov 24 2014
Will MacroGenics (MGNX) Continue to Surge Higher? Nov 24 2014
4 Biotech Catalyst Stocks to Buy With 60% to 100% Upside Potential Nov 20 2014
MACROGENICS INC Financials Nov 19 2014
MacroGenics (MGNX) in Focus: Stock Rises 7% in Session Nov 19 2014
MacroGenics to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
MacroGenics to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
MACROGENICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 12 2014
MACROGENICS INC Files SEC form 10-Q, Quarterly Report Nov 12 2014
MacroGenics Inc Earnings Call scheduled for 4:15 pm ET today Nov 11 2014
MacroGenics Provides Update on Corporate Progress and Third Quarter 2014 Financial Results Nov 11 2014
MacroGenics Provides Update on Corporate Progress and Third Quarter 2014 Financial Results Nov 11 2014
MacroGenics Announces Pre-clinical Data to be Presented at ASH 2014 Annual Meeting Nov 06 2014
MacroGenics to Present Pre-Clinical Data on MGD006 at 26th EORTC-NCI-AACR Symposium Oct 30 2014
MacroGenics to Present Pre-Clinical Data on MGD006 at 26th EORTC-NCI-AACR Symposium Oct 30 2014
MacroGenics Announces Date of Third Quarter 2014 Financial Results Conference Call Oct 28 2014
MacroGenics Announces Date of Third Quarter 2014 Financial Results Conference Call Oct 28 2014
MacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART... Sep 29 2014
Biotech Analyst Optimism: Price Targets Post-IPO Aug 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK